Therapeutic dose as the point of departure in assessing potential health hazards from drugs in drinking water and recycled municipal wastewater

Regulatory Toxicology and Pharmacology

Volumn 60, Issue 1, 2011, Pages 1-19

  Bull, Richard J ^a   Crook, James ^b   Whittaker, Margaret ^c   Cotruvo, Joseph A ^d  

^a MoBull Consulting   (United States)

^b Environmental Consulting Engineer   (United States)

^c ToxServices   (United States)

^d Joseph Cotruvo and Associates LLC   (United States)

Author keywords

Carcinogenic effects; Drinking water; Drugs or pharmaceuticals; Health effects assessment; Municipal wastewater; Reproductive and developmental effects; Therapeutic dose; Toxicity

Indexed keywords

CARCINOGEN; DRINKING WATER;

ADVERSE OUTCOME; ARTICLE; CARCINOGENIC ACTIVITY; DRUG CONTAMINATION; ENVIRONMENTAL EXPOSURE; FOOD AND DRUG ADMINISTRATION; HEALTH HAZARD; HUMAN; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; WASTE COMPONENT REMOVAL; WASTE MANAGEMENT; WASTE WATER RECYCLING; WATER ANALYSIS; WATER CONTENT; WATER QUALITY; WATER STANDARD;

ANIMALS; ANIMALS, LABORATORY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENTAL MONITORING; HUMANS; PHARMACEUTICAL PREPARATIONS; RECYCLING; RISK ASSESSMENT; WASTE DISPOSAL, FLUID; WATER POLLUTANTS, CHEMICAL; WATER PURIFICATION; WATER SUPPLY;

EID: 79956004095     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2009.12.010     Document Type: Article

References (95)

1. Ahmad M.U., Libbey L.M., Barbour J.F., Scanlan R.A. Isolation and characterization of products from the nitrosation of the alkaloid gramine. Fd. Chem. Toxic. 1985, 23(9):841-847.
2. Andersen M.E., Butenhoff J.L., Chang S.-C., Farrar D.G., Kennedy G.L., Lau C., Olsen G.W., Seed J., Wallace K.B. Perfluoroakyl acids and related chemistries - Toxicokinetics and modes of action. Toxicol. Sci. 2008, 102(1):3-14.
3. Anderson P.D., D'Aco V.J., Shanahan P., Chapra S.C., Buzby M.E., Cunningham V.L., Duplessie B.M., Hayes E.P., Mastrocco F.J., Parke N.J., Rader J.C., Samuelian J.H., Schwab B.W. Screening analysis of human pharmaceutical compounds in US surface waters. Environ. Sci. Technol. 2004, 38:838-849.
4. Australia, 2008. Australian Guidelines for Water Recycling (Phase 2) Augmentation of Drinking Water Supplies. 2008. Environmental Protection and Heritage Council, the Natural Resource Management Ministerial Council, and the Australian Health Ministers' Conference. May 2008. ISBN 1 921173 19 X.
5. Benotti M.J., Stanford B.D., Wert E.C., Snyder S.A. Evaluation of a photocatalytic reactor membrane pilot system for the removal of pharmaceuticals and endocrine disrupting compounds from water. Water Res. 2009, 43(6):1513-1522.
6. Bercu J.P., Parke N.J., Fiori J.M., Meyeroff R.D. Human health risk assessments for three neuropharmaceutical compounds in surface waters. Reg. Toxicol. Pharmacol. 2008, 50(3):420-427.
7. Boxall A.B.A., Fogg L.A., Kay P., Blackwell P.A., Pemberton E.J., Croxford A. Prioritization of veterinary medicines in the UK environment. Toxicol. Lett. 2003, 142:207-218.
8. Bruchet A., Prompsy C., Filippi G., Souali A. A broad spectrum analytical scheme for the screening of endocrine disruptors (EDs), pharmaceuticals and personal care products in wastewaters and natural waters. Water Sci. Technol. 2002, 46(3):97-104.
9. Bull R.J. Mode of action of liver tumor induction by trichloroethylene and its metabolites, trichloroacetate and dichloroacetate. Environ. Health Perspect. 2000, 108(Suppl. 2):241-259.
10. Bull, R.J., Reckhow, D.A., 2008. Use of chemical models and structure-activity relationships to identify novel disinfection by-products of potential toxicological concern. In: Karanfil, T., Krasner, S.W., Westerhoff, P., Xie, Y. (Eds.), Occurrence, Formation, Health Effects and Control of Disinfection By-Products in Drinking Water, Chapter 3. ACS Symposia Series, pp. 51-64.
11. Calamari D., Zuccato E., Castiglione S., Bagnati R., Fanell R. Strategic survey of therapeutic drugs in the rivers Po and Lambro in Northern Italy. Environ. Sci. Technol. 2003, 37:1241-1248.
12. CEPA (California Environmental Protection Agency). 1993. Safe Drinking Water and Toxic Enforcement Act of 1985) (Proposition 65) Status Report, No Significant Risk Levels for Carcinogens and Acceptable Intake Levels of Reproductive Toxicants Status Report. Office of Environmental Health Hazard Assessment, Sacramento, CA, USA.
13. Christensen F.M. Pharmaceuticals in the environment - A human risk?. Reg. Toxicol. Pharmacol. 1998, 28:212-221.
14. Contrera J.F., Matthews E.J., Kruhlak N.L., Benz R.D. Estimating the safe starting dose in phase I clinical trials and no observed effect level on QSAR modeling of the human maximum recommended daily dose. Regul. Toxicol. Pharmacol. 2004, 40:185-206.
15. Cotruvo J.A., Bull R.J., Crook J., Whittaker M. Identifying health effects concerns of the water reuse industry and prioritizing research needs for nomination of chemicals for research to appropriate National and International Agencies. WateReuse Project Report #06-004 2010, WateReuse Foundation, Washington DC.
16. Cunningham V.L., Binks S.P., Olson M.J. Human health risk assessment from the presence of human pharmaceuticals in the aquatic environment. Reg. Toxicol. Pharmacol. 2009, 53:39-45.
17. Daughton C.G., Ternes T.A. Pharmaceuticals and personal care products in the environment: agents of subtle change?. Environ. Health Perspect. 1999, 107(Suppl. 6):907-938.
18. Dostal L.A., Schardein J.L., Anderson J.A. Developmental toxicity of the HMG-CoA inhibitor, atorvastatin in rats and rabbits. Teratology 1994, 50(6):387-399.
19. Edison R.J., Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am. J. Med. Genet. A 2004, 131(3):287-298.
20. Eibl G. The role of PPAR-gamma and its interaction with COX-2 in pancreatic cancer. PPAR Res. 2008, 2008:326915.
21. Eichelbaum M., Kothe K.W., Hoffman F., von Unruh G.E. Kinetics and metabolism of carbamazepine during combined antiepileptic drug therapy. Clin. Pharmacol. Ther. 1979, 26(3):366-371.
22. Epstein D.L., Nolen G.A., Randall J.L., Christ S.A., Read E.J., Stober J.A., Smith M.K. Cardiopathic effects of dichloroacetate in the fetal Long-Evans rat. Teratology 1992, 46:225-235.
23. Facts and Comparisons® Version 4.0 2008, Facts and Comparisons, Wolters Kluwer, St. Louis, MO 63146.
24. Furst S.M., Uetrecht J.P. Carbamazepine metabolism to a reactive intermediate by the myeloperoxidase system of activated neutrophils. Biochem. Pharmacol. 1993, 45:1267-1275.
25. Godfrey E., Woessner W.W., Benotti M.J. Pharmaceuticals in on-site sewage treatment and ground water, western Montana. Ground Water 2007, 45(3):263-271.
26. Gold, L. S., Slone, T.H., Manley, M.B., Garfinkel, G.B., Ames, B.N., 2008. Carcinogen Potency Database (CPDB) [Online]. Available: <> March 15, 2008. http://potency.berkeley.edu/pub/tables/chemicalsummary.
27. Gonzalez F.J., Shah Y.M. PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 2008, 246(1):2-8.
28. Greene M., Harris HY.E.I.L., Gershensen D.M., et al. Mephalan may be a more potent leukemogen than cyclophosphamide. Ann. Int. Med. 1986, 105:360-367.
29. Henck J.W., Craft W.C., Black A., Colgin J., Anderson J.A. Pre- and postnatal toxicity of the HMG-CoA reductase inhibitor, atorvastatin in rats. Tox. Sci. 1998, 41(1):88-99.
30. Howdeshell K.L., Wilson V.S., Furr J., Lambright C.R., Rider C.V., Blystone C.R., Hotchkiss A.K., Gray L.E. A mixture of five phthalate esters inhibits fetal testicular testosterone production in the Sprague-Dawley rat in a cumulative, dose-additive manner. Toxicol. Sci. 2008, 105(1):153-165.
31. Hrab R.V., Hartman H.A., Cox R.H. Prevention of fluvastatin-induced toxicity, mortality, and cardiac myopathy in pregnant rats by mevalonic acid supplementation. Teratology 1994, 50(1):19-26.
32. Hynes J., Doubleday W.W., Dyckman A.J., Godfrey J.D., Grosso J.A., Kiau S., Leftheris K. N-amination of pyrrole and indole heterocycles with monochloramine (NH2Cl). J. Org. Chem. 2004, 69:1368-1371.
33. JECFA, 1873. Joint FAO/WHO Expert Committee on Food Additives. NMRS 53/TRS 539-JECFA 17/18.
34. JECFA, 2008. <>. http://www.who.int/ipcs/food/jecfa/en/.
35. Kim S.D., Cho J., Kim I.S., Vanderford B.J., Snyder S.A. Occurrence and removal of pharmaceuticals and endocrine disruptors in South Korean surface, drinking, and waste waters. Water Res. 2007, 41:1013-1021.
36. Klavarioti M., Mantzavinos D., Kassinos D. Removal of residual pharmaceuticals from aqueous systems by advanced oxidation processes. Environ. Int. 2008, 35(2):402-417.
37. Kolpin D.W., Furlong E.T., Meyer M.T., Thurman E.M., Zaugg S.D., Barber L.B., Buxton H.T. Pharmaceuticals, hormones, and other organic wastewater contaminants in US streams, 1999-2000: a national reconnaissance. Environ. Sci. Technol. 2002, 36:1202-1211.
38. Kostich M.S., Lazorchak J.M. Risks to aquatic organisms posed by human pharmaceutical use. Sci. Total Environ. 2008, 389:329-339.
39. Kroes R., Renwick A.G., Cheeseman M., Kleiner J., Mangelsdorf I., Piersma A., Schilter B., Schlatter J., van Schothorst F., Vos J.G., Würtzen G. Structure-based thresholds of toxicological concern (TTC): guidance for application to substances present at low levels in the diet. Food Chem. Toxicol. 2004, 42:65-83.
40. Kumar R., Wacker C.-D., Mende P., Spiegelhalder B., Preussmann R., Siddiqi M. Caffeine-derived N-nitroso compounds. II. Synthesis and characterization of nitrosation products from caffeidine and caffeidine acid. Chem. Res. Toxicol. 1993, 6:50-58.
41. Kümmerer K., Steger-Hartmann T., Meyer M. Biodegradability of the anti-tumor agent ifosfamide and its occurrence in hospital waste and communal sewage. Wat. Res. 1997, 31(11):2705-2710.
42. Kümmerer K. Drugs in the environment: emission of drugs, diagnostic aids and disinfectants into wastewater by hospitals in relation to other sources - a review. Chemosphere 2001, 45:957-969.
43. Lacy C.F., Armstrong L.L., Goldman M.P., Lance L.L. Drug Information Handbook 2007, Lexi-Comp, Hudson, OH. 15th ed.
44. Leadscope, 2008. FDA Toxicity Databases: Chemoinformatics Platform for Drug Discovery. <>. http://www.leadscope.com/.
45. Lishman L., Smyth S.A., Sarafin K., Kleywegt S., Toito J., Peart T., Lee B., Servos M., Beland M., Seto P. Occurrence and reductions of pharmaceuticals and personal care products and estrogens by municipal wastewater treatment plants in Ontario, Canada. Sci. Total Environ. 2006, 367:544-558.
46. Liu Z.C., Uetrecht J.P. Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. J. Pharmacol. Exp. Therapeut. 1995, 275:1476-1483.
47. Loraine G., Pettigrove M.E. Seasonal variations in concentrations of pharmaceuticals and personal care products in drinking water and reclaimed wastewater in Southern California. Environ. Sci. Technol. 2006, 40:687-695.
48. Masters B.A., Palmoski M.J., Flint O.P., Gregg R.E., Wang-Iverson D., Durham S.K. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin using neonatal rat skeletal myocytes. Toxicol. Appl. Pharmacol. 1995, 131(1):163-174.
49. Matsumoto M., Hirat-Koizumi M., Ema M. Potential adverse effects of phthalate acid esters on human health: a review of recent studies on reproduction. Regul. Toxicol. Pharmacol. 2008, 50(1):37-49.
50. Matthews E.J., Kruhlak N.L., Benz R.D., Contrera J.F. Assessment of health effects of chemicals in humans I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based upon clinical trial data. Curr. Drug Discovery Technol. 2004, 1:61-76.
51. Meaves, C., 2008. Facts and Comparisons staff. Personal communication, 08-06-08.
52. Mirvish S.S. Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC. Cancer Lett. 1995, 93:17-48.
53. Mitch W.A., Sedlak D.L. Factors controlling nitrosamine formation during wastewater chlorination. Water Sci. Technol.: Water Supply 2002, 2(3):191-198.
54. Miyamoto G., Zahid N., Uetrecht J.P. Oxidation of dichlofenac to reactive intermediates by neutrophils, myeloperoxidase, and hypochlorous acid. Chem. Res. Toxicol. 1997, 1997(10):414-419.
55. Nakajima T., Tanaka N., Sugiyama E., Kamijo Y., Hara A., Hu R., Li G., Li Y., Nakamura K., Gonzalez F.J., Aoyama T. Cholesterol-lowering effect of bezafibrate is independent of peroxisome proliferator-activated receptor activation in mice. Biochem. Pharmacol. 2008, 76(1):108-119.
56. Copper in Drinking Water 2000, NRC, National Research Council, National Academy Press, Washington, DC.
57. NTP, 1993. Toxicology and carcinogenesis studies of 5,5-diphenylhydantoin (CAS No. 57-41-0)(Phenytoin) in F344/N rats and B6C3F1 mice (Feed studies). TR-404 - National Toxicology Program, NIEHS, Research Triangle Park, NC.
58. NTP, 2008. Toxicology and carcinogenesis studies of ethinyl estradiol (CAS No. 57-63-6) in Sprague-Dawley rats (Feed studies). TR-548 - Abstract - National Toxicology Program. <>. http://ntp.niehs.nih.gov/?objectid=D7C7E75B-F1F6-975E-7960632E81DA3E97.
59. NTP, 2009. National Toxicology Program Website. <>. http://ntp-server.niehs.nih.gov/.
60. Pessayre D. Role of reactive metabolites in drug-induced hepatitis. J. Hepatol. 1995, 23(Suppl. 1):16-24.
61. Pinkston R.E., Sedlak D.L. Transformation of aromatic ether and amine-containing pharmaceuticals during chlorine disinfection. Environ. Sci. Technol. 2004, 38:4019-4025.
62. Price R.L., Carver W., Simpson D.G., Fu L., Zhao J., Borg T.K., Terracio L. The effects of angiotensin II and specific antagonist receptor blockers on embryonic cardiac development and looping patterns. Dev. Biol. 1997, 192(2):572-584.
63. Razda R., Frei E., Spiegelhalder B., Siddiqi M. Caffeine-derived N-nitroso compounds. IV. Kinetics of mononitrosocaffeidine demethylation by rat liver microsomes. Cancer Lett. 1994, 79(1):117-122.
64. Reijneveld J.C., Root R.W., Bredman J.J., Joles J.A., Bar P.R. Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on development of young rats. Pediatr. Res. 1996, 39(6):1028-1035.
65. Rider C.V., Furr J., Wilson V.S., Gray L.E. A mixture of seven antiandrogens induces reproductive malformations in rats. Int. J. Androl. 2008, 31:249-262.
66. RxList, 2007. <>. http://www.rxlist.com/script/main/hp.asp.
67. Rusyn I., Peters J.M., Cunningham M.L. Modes of action and species-specific effects of di-(2-ethylhexyl)phthalate in the liver. Crit. Rev. Toxicol. 2006, 36(5):459-479.
68. Sanderson J.T. The steroid biosynthesis pathway as a target for endocrine-disrupting chemicals. Toxicol. Sci. 2006, 94(1):3-21.
69. Schmahl D., Habs M. Carcinogenic action of low-dose cyclophosphamide giver orally to Sprague-Dawley rats in a lifetime experiment. Int. J. Cancer 1979, 23:706-712.
70. Schulman L.J., Sargent E.V., Naumann B.D., Faria E.C., Dolan D.G., Wargo J.P. A human health risk assessment of pharmaceuticals in the aquatic environment. Hum. Ecol. Risk Assess. 2002, 8:657-680.
71. Schwab B.W., Hayes E.P., Fiori J.M., Mastrocco F.J., Roden N.M., Cragin D., Meyeroff R.D., D'Aco V.J., Anderson P.D. Human pharmaceuticals in US surface waters: a human health risk assessment. Regul. Toxicol. Pharmacol. 2005, 42:296-312.
72. Sedlak D.L., Pinkston K., Huang C.-H. Occurrence survey of pharmaceutically active compounds 2005, Awwa Research Foundation, Denver, CO.
73. Spence S.G., Allen H.L., Cukierski M.A., Manson J.M., Robertson R.T., Eydelloth R.S. Defining the susceptible period of developmental toxicity for the AT1-selective angiotensin II receptor antagonist losartan in rats. Teratology 1995, 51(6):367-382.
74. Spence S.G., Cukierski M.A., Manson J.M., Robertson R.T., Eydelloth R.S. Evaluation of the reproductive and developmental toxicity of the ATI-selective angiotensin II receptor antagonist losartan in rats. Teratology 1995, 51(6):383-397.
75. Spence S.G., Zacchei A.G., Lee L.L., Baldwin C.L., Berna R.A., Mattson B.A., Eydelloth R.S. Toxicokinetic analysis of losartan during gestation and lactation in the rat. Teratology 1996, 53(4):245-252.
76. Stacpoole P.W., Harwood H.J., Varnado C.E. Regulation of rat liver hydroxymethylglutaryl Coenzyme A reductase by a new class of noncompetitive inhibitors. J. Clin. Invest. 1983, 72:1575-1585.
77. Steger-Hartmann T., Kümmer K., Schecker J. Trace analysis of the antineoplastics ifosfamide in the sewage water by two-step solid phase extraction and gas-chromatography-mass spectrometry. J. Chromatogr. A 1996, 726:179-184.
78. Steger-Hartmann T., Kümmer K., Hartmann A. Biological degradation of cyclophosphamide and its occurrence in sewage water. Ecotoxicol. Environ. Safety 1997, 36:174-177.
79. Ternes T. The occurrence of micropollutants in the aquatic environment: a new challenge for water management. Water Sci. Technol. 2007, 55(12):327-332.
80. Thomas P.M., Foster G.D. Tracking acidic pharmaceuticals, caffeine, and triclosan through the wastewater treatment process. Environ. Toxicol. Chem. 2005, 24(1):25-30.
81. Uetrecht J.P., Ma H.M., MacKnight E., McClelland R. Oxidation of aminopyrine by hypochlorite to a reactive dication: possible implications for aminopyrine induced agranulocytosis. Chem. Res. Toxicol. 1995, 8:226-233.
82. Uetrecht J.P., Zahid N. N-Chlorination and oxidation of procainamide by myeloperoxidase: toxicological implications. Chem. Res. Toxicol. 1991, 4:218-222.
83. US EPA, 2000. Supplementary Guidance for Conducting Health Risk Assessment of Chemical Mixtures. EPA/630/R-00/002.
84. US EPA, 2002. A Review of the Reference Dose and Reference Concentration Processes. EPA/630/P-02/002F. Final Report December, 2002.
85. US EPA, 2005. Guidelines for Carcinogen Risk Assessment. EPA/630/P-03/001F. Final report, March 2005.
86. US EPA, 2008a. Contaminant Candidate List 3 Chemicals: Classification of the PCCL to CCL. EPA 815-R-08-004, Feb. 2008 draft. EPA Office of Ground Water and Drinking Water. <>. http://www.epa.gov/safewater.
87. US EPA, 2008b. Chemicals Reported in Articles Reviewed from the OW PPCP Inventory. COMPREHENSIVE TABLE (Inventory July 3, 2008).
88. US FDA, 2005. US Food and Drug Administration. CDER Report to the Nation 2005: Improving Public Health through Human Drugs. Rockville, MD. <>. http://www.fda.gov/cder/reports/rtn/2005/rtn2005.pdf.
89. US FDA, 2007. US Food and Drug Administration Maximum Recommended Therapeutic Dose (MRTD) Database. <>. http://www.fda.gov/cder/Offices/OPS_IO/MRTD.htm.
90. US FDA, 2008a. US Food and Drug Adminstration. Drug Information. Preventable Adverse Drug Reactions: A Focus on Drug Interactions. <>. http://www.fda.gov/CDER/DRug/drugReactions/default.htm.
91. US FDA, 2008b. US Food and Drug Administration. Index to Drug-Specific Information. <>. http://www.fda.gov/cder/DrugSafety/DrugIndex.htm.
92. US FDA, 2008c. US Food and Drug Administration. Office of Non-Prescription Drugs: Consumer Information: Safe Use of Over-the-Counter Drug Products. <>. http://www.fda.gov/cder/offices/OTC/consumer.htm.
93. US FDA, 2008d. US Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. <>. http://www.accessdatga.fda.gov/scripts/medwatch.
94. Watts, C., Maycock, D., Crane, M., Fawell, J., 2007. Desk Based Review of Current Knowledge of Pharmaceuticals in Drinking Water and Estimation of Potential Levels. Watts and Crane Associates Final Report to Drinking Water Inspectorate of UK Contract No. CSA7184/WT02046/DWI 70/2/213.
95. Webb S., Ternes T., Gibert M., Olejniczak K. Indirect human exposure to pharmaceuticals via drinking water. Toxicol. Lett. 2003, 142:157-167.